Inflammatory response in lungs and extrapulmonary sites detected by [18F] fluorodeoxyglucose PET/CT in convalescing COVID-19 patients tested negative for coronavirus

Yan Bai, Junling Xu, Lijuan Chen, Chang Fu, Yi Kang, Weifeng Zhang, Georges El Fakhri, Jianqin Gu, Fengmin Shao, Meiyun WangEuropean 2021 · DOI

Introduction

As the global medical community transitioned from managing the acute phase of the COVID-19 pandemic to understanding its long-term sequelae, a significant clinical paradox emerged. Many patients who had successfully cleared the SARS-CoV-2 virus—confirmed by consecutive negative RT-PCR tests—continued to experience persistent symptoms. While standard anatomical imaging, such as chest CT, is effective at identifying structural damage like fibrosis or ground-glass opacities, it often fails to distinguish between inactive scarring and active, ongoing inflammation.

This study, published in the European Journal of Nuclear Medicine and Molecular Imaging, utilizes [18F] fluorodeoxyglucose (FDG) PET/CT to provide a metabolic assessment of patients in the convalescent phase. By measuring glucose metabolism, the researchers aimed to determine whether systemic inflammation persists after viral clearance and to map the extent of this activity across pulmonary and extrapulmonary sites.

Methodology

The researchers conducted a prospective study in February 2020, focusing on seven patients (mean age 48.1 years) recovering from severe COVID-19. All patients met the strict inclusion criterion of having at least two consecutive negative RT-PCR tests for SARS-CoV-2 prior to imaging.

The primary imaging modality was [18F] FDG PET/CT. FDG, a glucose analog, is preferentially taken up by metabolically active cells. In the context of infection, inflammatory cells such as activated macrophages and neutrophils exhibit high glucose demand, making them visible on PET scans. To establish a baseline, the study included a control group of seven age- and sex-matched individuals who underwent PET/CT for non-inflammatory indications.

Quantitative analysis involved measuring Standardized Uptake Values (SUVmax and SUVavg) and CT attenuation (Hounsfield units) across multiple regions of interest, including the lungs, mediastinal lymph nodes, liver, spleen, heart, kidneys, and brain. These metabolic markers were then correlated with clinical laboratory data, such as white blood cell counts and C-reactive protein levels.

Results

The metabolic imaging revealed a stark contrast between convalescent patients and healthy controls, highlighting a systemic inflammatory "tail" that outlasts the viral infection.

Pulmonary Findings

In the lungs, residual lesions identified on CT scans showed significantly elevated metabolic activity. The mean SUVmax for these pulmonary lesions was 3.44 ± 0.71, compared to a baseline of 0.54 ± 0.22 in the healthy lung tissue of controls ($p < 0.01$). Notably, the study observed that metabolic inflammation often persisted in lung regions that appeared structurally normal on conventional CT, suggesting that metabolic recovery lags behind anatomical resolution.

Extrapulmonary Inflammation

The most significant finding was the involvement of multiple organ systems beyond the respiratory tract:

  • Mediastinal Lymph Nodes: Convalescent patients exhibited a mean SUVmax of 3.60 ± 1.45, significantly higher than the 1.44 ± 0.55 observed in controls ($p = 0.026$).
  • Liver and Spleen: Both organs showed increased FDG uptake. The liver SUVmax was 4.31 ± 0.75 (vs. 2.86 ± 0.45, $p = 0.017$), and the spleen SUVmax was 3.31 ± 1.14 (vs. 2.20 ± 0.38, $p = 0.017$).
  • Brain Metabolism: Interestingly, no significant differences were found in brain metabolism between the two groups. This suggests that the "brain fog" often reported by patients may not be associated with the gross metabolic shifts detectable by FDG PET at this stage of recovery.

Clinical Correlations

A strong negative correlation was found between the metabolic activity in the spleen and peripheral blood lymphocyte counts. This suggests that the spleen may act as a site for immune cell sequestration or increased turnover during the post-viral inflammatory phase.

Discussion

The findings of this study suggest that COVID-19 is a systemic disease with an inflammatory profile that does not immediately resolve upon viral clearance. The persistence of high FDG uptake in the lungs, liver, spleen, and lymph nodes of RT-PCR-negative patients indicates that the immune system remains in a state of heightened activation.

This "metabolic footprint" of recovery provides a potential biological basis for the lingering symptoms observed in many patients. The decoupling of viral presence and inflammatory response suggests that post-acute management may require targeted anti-inflammatory strategies rather than just antiviral focus.

Limitations and Future Directions

While the study provides critical insights, it is limited by its small sample size (n=7) and its cross-sectional design, which captured only a single point in time during recovery. Furthermore, the lack of histological confirmation (biopsy) means that while the FDG uptake is consistent with inflammation, the specific cellular drivers remain inferred. Future longitudinal studies are necessary to track the resolution of these metabolic signals and to determine if they can serve as predictive biomarkers for "Long COVID."

Summary updated

BibTeX
@inproceedings{bai2021inflammatory,
  author = {Yan Bai and Junling Xu and Lijuan Chen and Chang Fu and Yi Kang and Weifeng Zhang and Georges El Fakhri and Jianqin Gu and Fengmin Shao and Meiyun Wang},
  title = {{Inflammatory response in lungs and extrapulmonary sites detected by [18F] fluorodeoxyglucose PET/CT in convalescing COVID-19 patients tested negative for coronavirus}},
  booktitle = {European},
  year = {2021},
  doi = {10.1007/s00259-020-05083-4},
}
Figure